Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Milestone — Revenue Recognition Milestone Method Pending

Similar metrics at other companies

Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K—
Rivian Automotive, Inc. logo
RIVNTesting Milestone Payments — Receivable, contingent on milestone achievement
$1B0.0%
Axsome Therapeutics logo
AXSMRoyalty And Milestone Revenue — Revenue
$1.8M+63.2%
CRISPR Therapeutics logo
CRSPCollaborative Arrangement Material Rights — Milestone Payment Receivable
$410M0.0%
Insmed logo
INSMPayment Of Milestone
$15M—
Ionis Pharmaceuticals logo
IONSMaximum Amount Of Payments Receivable For Additional Milestones
$625M—

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
Enterprise value$3.88B+565%
P/S1,465.1×+962×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept dnth:RevenueRecognitionMilestoneMethodPending.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's milestone — revenue recognition milestone method pending.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's milestone — revenue recognition milestone method pending?
Dianthus Therapeutics (DNTH) reported milestone — revenue recognition milestone method pending of $15M in Q1 2026.
How has Dianthus Therapeutics's milestone — revenue recognition milestone method pending changed year-over-year?
Dianthus Therapeutics's milestone — revenue recognition milestone method pending decreased by 0.0% year-over-year, from $15M to $15M.
What does milestone — revenue recognition milestone method pending mean?
This metric represents revenue associated with specific clinical or regulatory milestones that has not yet been recognized under the company's accounting policy. It reflects the value of contingent payments from collaborative partners that are awaiting the achievement of defined performance criteria or regulatory approval. Tracking this helps investors understand the potential future revenue pipeline tied to successful development outcomes.